Furthest along
16 approved
12 in Phase 3
Drugs
94
in active trials · 193 in all
Trials
242 active
807 since 2021
Drugs94
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
GIP + GLP-1 |
Approved | Nov 2026soonPhase 3 trial completes | |||
| How it works | Copies two gut hormones | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 11 more | ||||
| Open drug page | |||||
GLP-1 + glucagon |
Innovent |
Approved in China | 31 Dec 2026Phase 3 trial completes | ||
| How it works | Copies two hormones | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 8 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | Feb 2027Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Breast Cancer, Breast Neoplasms and 29 more | ||||
| Open drug page | |||||
Oral small-molecule GLP-1 |
Approved | Feb 2027Phase 3 trial completes | |||
| How it works | A pill that switches on the GLP-1 receptor | ||||
| Next date | Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Overweight, Obesity and 26 more | ||||
| Open drug page | |||||
Insulin analog |
Approved | Mar 2027Phase 1 trial completes | |||
| Next date | Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Diabetes Mellitus, Type 1, Type 2 diabetes | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 25 Apr 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 25 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis, Eczema and 4 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | May 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | May 2027 · Phase 2 trial completes | ||||
| Also tested for | Ulcerative Colitis, Crohn's Disease and 10 more | ||||
| Open drug page | |||||
VEGFR2 antibody |
Approved | May 2027Phase 2 trial completes | |||
| Next date | May 2027 · Phase 2 trial completes | ||||
| Also tested for | Metastatic Non-Small Cell Lung Cancer, Biliary Tract Cancer and 5 more | ||||
| Open drug page | |||||
Estrogen receptor antagonist |
Approved | Oct 2027Phase 3 trial completes | |||
| How it works | Blocks oestrogen from acting on cells | ||||
| Next date | Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Breast Neoplasms, Breast Cancer and 5 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | Oct 2027Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | Oct 2027 · Phase 3 trial completes | ||||
| Also tested for | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and 9 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | Nov 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Alzheimer Disease, Dementia and 13 more | ||||
| Open drug page | |||||
GLP-1 receptor agonist |
Approved | Dec 2027Phase 3 trial completes | |||
| How it works | Copies GLP-1 | ||||
| Next date | Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Type 2 diabetes | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved | Mar 2028Phase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Diabetes Mellitus, Type 1, Juvenile Idiopathic Arthritis and 8 more | ||||
| Open drug page | |||||
RET inhibitor |
Approved | Oct 2029Phase 4 trial completes | |||
| Next date | Oct 2029 · Phase 4 trial completes | ||||
| Also tested for | Medullary Thyroid Cancer, Non-Small Cell Lung Cancer and 9 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | — | |||
| How it works | An antibody | ||||
| Also tested for | Episodic Migraine, Chronic Migraine | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | — | |||
| How it works | An antibody | ||||
| Also tested for | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | ||||
| Open drug page | |||||
GIP + GLP-1 + glucagon |
Phase 3 | Nov 2026soonPhase 3 trial completes | |||
| How it works | Copies three hormones at once | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 7 more | ||||
| Open drug page | |||||
— |
Phase 3 | Feb 2027Phase 2 trial completes | |||
| Next date | Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Overweight, Obesity and 13 more | ||||
| Open drug page | |||||
Amylin |
Phase 3 | Mar 2027Phase 2 trial completes | |||
| How it works | Copies amylin | ||||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Obesity, Overweight and 12 more | ||||
| Open drug page | |||||
— |
Phase 3 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms and 5 more | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings33
Since Feb 2024 · All on SEC.gov- 29 OctReported quarterly results · SEC 8-K
- 5 AugReported quarterly results · SEC 8-K
- 20 MayReported other events · SEC 8-K
- 8 MayOffered new securities · 1 prospectus (424B2)
- 7 MayFiled a report · SEC 8-K
- 6 MayOffered new securities · 1 prospectus (424B2)
- 30 AprReported quarterly results · SEC 8-K
- 4 FebReported quarterly results · SEC 8-K
- 21 Nov 2025Changed a director or officer · SEC 8-K
- 30 Oct 2025Reported quarterly results · SEC 8-K
- 20 Aug 2025Reported other events · SEC 8-K
- 18–19 Aug 2025Offered new securities · 2 prospectuses (424B2)
- 7 Aug 2025Reported quarterly results · SEC 8-K
- 8 May 2025Filed a report · SEC 8-K
- 1 May 2025Reported quarterly results · SEC 8-K
- 12 Feb 2025Reported other events · SEC 8-K
- 10–11 Feb 2025Offered new securities · 2 prospectuses (424B2)
- 6 Feb 2025Reported quarterly results · SEC 8-K
- 14 Jan 2025Reported quarterly results · SEC 8-K
- 19 Nov 2024Changed a director or officer · SEC 8-K
- 30 Oct 2024Reported quarterly results · SEC 8-K
- 9 Sep 2024Changed a director or officer · SEC 8-K
- 16 Aug 2024Changed a director or officer · SEC 8-K
- 14 Aug 2024Reported other events · SEC 8-K
- 12–13 Aug 2024Offered new securities · 2 prospectuses (424B2)
- 8 Aug 2024Reported quarterly results · SEC 8-K
- 10 Jul 2024Changed a director or officer · SEC 8-K
- 5 Jun 2024Changed a director or officer · SEC 8-K
- 9 May 2024Filed a report · SEC 8-K
- 30 Apr 2024Reported quarterly results · SEC 8-K
- 9 Feb 2024Reported other events · SEC 8-K
- 7–8 Feb 2024Offered new securities · 2 prospectuses (424B2)
- 6 Feb 2024Reported quarterly results · SEC 8-K
About
- No active trial
- 99 other drugs
- Registry names
- 8 names in ClinicalTrials.gov Eli Lilly and Company
Loxo Oncology, Inc.
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company - Sources
- ClinicalTrials.gov updated 16 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev